** Shares of diabetes device makers fall between 1% to 3% before the bell
** Eli Lilly LLY.N says its oral drug orforglipron led to an average weight loss of 7.9% and lowered blood sugar for overweight patients with type 2 diabetes in a late-stage trial
** Shares of Dexcom DXCM.O, which manufactures continuous glucose monitors, down 2.6% at $66.94 premarket
** Shares of insulin pump makers Tandem Diabetes Care TNDM.O and Insulet Corp PODD.O down around 2% each
** LLY shares rise 13.4% to $833.56 premarket
** As of last close, DXCM down 11.6%, TNDM down 52.1%, LLY down 4.8%, PODD down 4% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。